Aprea Therapeutics News

Aprea Therapeutics Appoints Mirza As CMO

RTTNewsMay 2 22:01

Press Release: Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) New role enhances company's stron

Dow JonesMay 2 21:15

Aprea Therapeutics' Promising Cancer Drug Candidate Warrants Buy Rating

TipRanksApr 12 23:35

Optimistic Outlook for Aprea Therapeutics' Oncology Pipeline: A Comprehensive Buy Rating Analysis

TipRanksApr 11 18:26

Aprea Therapeutics Announces Presentations on Its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics, Inc. (Nasdaq: APRE) today released details about four poster presentations at the ongoing American Association of Cancer Research (AACR) Annual Meeting, taking place April 5 to 10, 2024 in San Diego, CA.

GlobeNewswireApr 11 00:00

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 85.5% to $4.86 during Thursday's pre-market session. The market value of their outstanding shares is at $800.0 million. Candel Therapeutics (NASDAQ

BenzingaApr 4 20:09

Aprea Therapeutics Files to Sell 4.39M Shares of Common Stock for Holders

Seeking AlphaApr 4 04:30

Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating

TipRanksMar 28 04:05

Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)

TipRanksMar 27 20:20

Aprea Therapeutics Is Maintained at Outperform by Wedbush

Aprea Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesMar 27 20:02

Wedbush Maintains Outperform on Aprea Therapeutics, Raises Price Target to $11

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics with a Outperform and raises the price target from $9 to $11.

Analyst UpgradesMar 27 19:54

Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow JonesMar 26 23:22

Aprea Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Aprea Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 26 23:22

Buy Rating Affirmed: Aprea Therapeutics Poised for Growth With Strong Pipeline Momentum Into 2024

TipRanksMar 26 23:15

HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics with a Buy and maintains $20 price target.

Analyst UpgradesMar 26 23:12

Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading

US stocks looked set to open modestly higher Tuesday as investors parsed durable goods and home price data and looked ahead to a key consumer confidence gauge. Dow Jones Industrial Average futures wer

MT NewswiresMar 26 21:29

Aprea Therapeutics: Q4 Earnings Insights

Aprea Therapeutics (NASDAQ:APRE) reported its Q4 earnings results on Tuesday, March 26, 2024 at 07:45 AM.Here's what investors need to know about the announcement.EarningsAprea Therapeutics missed est

BenzingaMar 26 21:10

Aprea Therapeutics GAAP EPS of -$0.92

Seeking AlphaMar 26 20:05

Aprea Therapeutics 4Q Loss/Shr 92c >APRE

Aprea Therapeutics 4Q Loss/Shr 92c >APRE

Dow JonesMar 26 19:45

Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline

TipRanksMar 20 03:05